Phosphatidylinositol-3-kinase (Pi3K) inhibitors
- Name
- Phosphatidylinositol-3-kinase (Pi3K) inhibitors
- Accession Number
- DBCAT005750
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Idelalisib An antineoplastic kinase inhibitor used to treat chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). Duvelisib An inhibitor of phosphatidylinositol 3-kinase delta and gamma used to treat relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Alpelisib Alpelisib is indicated in combination with fulvestrant to treat postmenopausal women, and men, with advanced or metastatic breast cancer. This cancer must be hormone receptor (HR)-positive, human epidermal growth factor... Copanlisib A PI3K inhibitor used to treat relapsed follicular lymphoma in adults. Parsaclisib Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)). - Drugs & Drug Targets